IDRA-21 and Benzothiadiazine AMPA Receptor Modulators: Molecular Pharmacology, Preclinical Cognition and Safety Limitations

Positive allosteric modulators (PAMs) of AMPA receptors have been investigated as potential cognitive enhancers, but glutamate-dependent potentiation does not eliminate excitotoxic risk. IDRA-21 is an orally active benzothiadiazine derivative with preclinical effects on learning and memory in rodents and non-human primates. This narrative review evaluates its receptor pharmacology, metabolic instability, behavioural evidence and safety limitations, and compares these findings with subsequent medicinal chemistry. IDRA-21 has low affinity for an engineered isolated GluA2 ligand-binding domain and low functional potency in several electrophysiological preparations. Its pharmacology is not restricted to AMPA receptors: direct kainate receptor potentiation, NMDA current inhibition and effects on GABA-mediated currents have also been reported. Hydrolysis to an active metabolite complicates attribution of in vivo effects to the parent compound. The absence of detectable toxicity at selected concentrations in cerebellar cultures contrasts with increased hippocampal injury after global ischemia in rats. Later benzothiadiazines, including BPAM363, show encouraging preclinical profiles, but neither potency alone nor results from a single injury model establish a general safety advantage. No peer-reviewed human administration study of IDRA-21 was identified in the sources examined. IDRA-21 therefore remains a preclinical reference compound whose translational interpretation requires exposure data, receptor-context-specific pharmacology and independently replicated safety studies.